Pfenex (PFNX) 10-Q 29 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 25, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'PFNX	'
Entity Registrant Name	'Pfenex Inc.	'
Entity Central Index Key	'0001478121	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	20,342,836

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$3,941	$3,954
Short-term investments	'	1,250
Accounts and unbilled receivables, net	1,355	3,461
Inventories finished goods	18	26
Income tax receivable	401	398
Deferred income taxes	3,481	3,481
Other current assets	1,519	284
Total current assets	10,715	12,854
Restricted cash	4,030	4,029
Property and equipment, net	2,102	2,329
Notes receivable from related parties	'	95
Other long term assets	36	36
Intangible assets, net	6,628	6,893
Goodwill	5,577	5,577
Total assets	29,088	31,813
Current liabilities:	'	'
Accounts payable	1,127	1,804
Accrued liabilities	4,570	2,953
Deferred revenue	997	1,253
Line of credit obligation	3,813	'
Total current liabilities	10,507	6,010
Deferred tax liability	3,481	3,481
Line of credit obligation	'	3,590
Other long-term liabilities	3	3
Total liabilities	13,991	13,084
Commitments and contingencies (Notes 9 and 10)	'	'
Stockholders' equity (deficit):	'	'
Common stock, $0.001 par value, 30,000,000 and 12,514,224 shares authorized at June 30, 2014 and December 31, 2013, respectively, 1,571,473 and 1,541,781 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	4	2
Additional paid-in capital	'	'
Accumulated deficit	-98,847	-94,453
Total stockholders' deficit	-98,843	-94,451
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	29,088	31,813
Redeemable Convertible Series A- 2 Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable convertible preferred stock	49,400	49,200
Redeemable Convertible Series A- 1 Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable convertible preferred stock	$64,540	$63,980

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Common stock, par value	$0.00	$0.00
Common stock, authorized	30,000,000	12,514,224
Common stock, issued	1,571,473	1,541,781
Common stock, outstanding	1,571,473	1,541,781
Redeemable Convertible Series A- 2 Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, par value	$0.00	$0.00
Redeemable convertible preferred stock, shares authorized	5,000,000	4,978,662
Redeemable convertible preferred stock, shares issued	3,556,186	3,556,186
Redeemable convertible preferred stock, shares outstanding	3,556,186	3,556,186
Redeemable convertible preferred stock, liquidation preference	$13,815,111	$13,815,111
Redeemable Convertible Series A- 1 Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, par value	$0.00	$0.00
Redeemable convertible preferred stock, shares authorized	5,000,000	4,978,662
Redeemable convertible preferred stock, shares issued	4,978,661	4,978,661
Redeemable convertible preferred stock, shares outstanding	4,978,661	4,978,661
Redeemable convertible preferred stock, liquidation preference	$16,470,071	$16,470,071

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue	$3,266	$2,309	$5,824	$5,694
Cost of revenue	2,544	1,306	4,452	3,335
Gross profit	722	1,003	1,372	2,359
Operating expenses:	'	'	'	'
Selling, general and administrative	2,024	1,676	3,519	3,459
Research and development	860	1,272	1,538	2,052
Total operating expenses	2,884	2,948	5,057	5,511
Loss from operations	-2,162	-1,945	-3,685	-3,152
Other expense, net	-21	-9	-39	-10
Net loss before income taxes	-2,183	-1,954	-3,724	-3,162
Income tax benefit (expense)	'	777	-1	1,259
Net loss	-2,183	-1,177	-3,725	-1,903
Effective preferred stock dividends	-447	-419	-882	-827
Net loss attributable to common stockholders	($2,630)	($1,596)	($4,607)	($2,730)
Net loss per common share basic and diluted	($1.67)	($1.04)	($2.95)	($1.80)
Weighted-average common shares used to compute basic and diluted net loss per share	1,571	1,542	1,560	1,520

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($3,725)	($1,903)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	233	229
Amortization of intangible assets	265	265
Deferred income taxes	'	-1,259
Stock-based compensation expense	84	67
Changes in operating assets and liabilities:	'	'
Accounts and unbilled receivables	2,106	1,013
Inventories	8	738
Other current assets	-1,235	324
Notes receivable	95	-1
Accounts payable	-677	-1,515
Accrued expenses	1,617	1,137
Deferred revenue	-256	-2,143
Income tax (receivable) payable	-3	66
Net cash used in operating activities	-1,488	-2,982
Cash flow from investing activities	'	'
Purchases of investments	'	-4,247
Sales/maturities of investments	1,250	2,000
Acquisitions of property and equipment	-6	-97
Proceeds from sales of equipment and assets held for sale	'	2
Net cash provided by (used in) investing activities	1,244	-2,342
Cash flows from financing activities	'	'
Borrowings under line of credit agreement	223	153
Restricted cash	-1	-9
Proceeds from exercise of stock options	9	24
Net cash provided by financing activities	231	168
Net decrease in cash and cash equivalents	-13	-5,156
Cash and cash equivalents	'	'
Beginning of period	3,954	7,966
End of period	3,941	2,810
Supplemental schedule of cash flow information	'	'
Cash paid for interest	43	16
Cash paid for taxes	13	16
Non-cash financing transactions	'	'
Transfer of investments to pledged accounts	'	3,000
Accretion of preferred stock dividends	$760	$35,340

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Organization and Summary of Significant Accounting Policies	'
	1. Organization and Summary of Significant Accounting Policies
	Business Activities and Organization
	Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. Pfenex is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc. a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with trial completion expected in the fourth quarter of 2014, and expects to commence a Phase 3 trial in mid-2015 with results expected in 2017. The Company intends to commercialize PF582 with its own internal sales and marketing capabilities in North America and Europe. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. The Company plans to initiate a Phase 1 trial in the second half of 2014. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates.
	The Company’s revenue is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
	Reverse Stock Split
	On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.
	Initial Public Offering
	In July 2014, the Company completed its initial public offering in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.3 million. In connection with the initial public offering, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed financial statements included the accounts of the Company and its wholly owned subsidiary.
	These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013 included in the Company’s Prospectus filed with the SEC on July 24, 2014 pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2013 has been derived from the audited financial statement at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	Use of Estimates
	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
	Restricted Cash
	In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”). Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013. The two lines of credit are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the lines of credit are paid in full and have expired. The lines of credit are due and payable in full in April 2015.
	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of June 30, 2014 and December 31, 2013. For the Company’s cash position of $8.0 million as of June 30, 2014, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.
	Additional credit risk is related to the Company’s concentration of receivables. As of June 30, 2014, receivables were concentrated among two customers representing 87% of total gross receivables and three customers as of December 31, 2013, representing 83%. For the six month period ended June 30, 2014, revenue was concentrated among two customers representing 78% of total revenues and three customers representing 72% for the six months ended June 30, 2013. Revenue was concentrated among two customers for each of the three months ended June 30, 2014 and 2013, representing 80% and 57% of total revenue, respectively. There were no supplier concentrations.
	A portion of revenue is earned from sales outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the three and six months ended June 30, 2013 and 2014 is as follows (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	US Revenue	$	2,931	$	1,944	$	5,158	$	3,237
	Non-US Revenue	$	335	$	365	$	666	$	2,457
	During the three and six months ended June 30, 2014, and the three months ended June 30, 2013, no single foreign country accounted for more than 10% of the Company’s revenue. During the six months ended June 30, 2013, revenue earned from non-recurring sales in The Netherlands accounted for approximately 15% of the Company’s revenue.
	Inventories
	Inventories consist of work in progress and finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the six months ended June 30, 2014 or the year ended December 31, 2013.
	Revenue
	The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for milestones and product royalties.
	The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.
	Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.
	Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.
	The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under our government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
	The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the three and six months ended June 30, 2014, and 2013, no revenue in connection with the achievement of milestones has been recognized.
	The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 90 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. Reagent product revenue amounted to $0.3 million and $0.2 million for the three months ended June 30, 2014 and 2013, respectively, and $0.8 million and $2.3 million for the six months ended June 30, 2014 and 2013, respectively. As of June 30, 2014, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has deemed it prudent to reserve $14 thousand and $18 thousand for warranty and return rights at June 30, 2014 and December 31, 2013, respectively. The reserve is component of accounts and unbilled receivables, net in the accompanying Balance Sheets.
	Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting recording the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.
	Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be the first quarter of fiscal year 2018 using one of two retrospective application methods. The Company is currently evaluating the impact of the adoption of this accounting standard update on its financial statements.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
	2. Fair Value Measurements
	Authoritative guidance defines fair value, establishes a framework for measuring fair value in U.S. GAAP and requires disclosures about fair value measurements.
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
		Level 1		Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at June 30, 2014 and December 31, 2013 included the Company’s cash, cash equivalents and investments in certificates of deposit. There were no Level 1 liabilities;
		Level 2		Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at June 30, 2014 or December 31, 2013; and
		Level 3		Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at June 30, 2014 or December 31, 2013.
	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013, were determined using the inputs described above and are as follows:
		Total			Fair Value Measurements at Reporting Date Using
	(in thousands)				Quoted Prices			Significant		Significant
					in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical Assets			Inputs		(Level 3)
					(Level 1)			(Level 2)
	June 30, 2014
	Classified as current assets:
	Cash and money market funds	$	7,971		$	7,971		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		7,971			7,971			—		—
	Less cash, cash equivalents and restricted cash		(7,971	)		(7,971	)		—		—
	Total investments	$	—		$	—		$		$	—
	December 31, 2013
	Classified as current assets:
	Cash and money market funds	$	7,983		$	7,983		$	—	$	—
	Certificates of deposit		1,250			1,250			—		—
	Total		9,233			9,233			—		—
	Less cash, cash equivalents and restricted cash		(7,983	)		(7,983	)		—		—
	Total investments	$	1,250		$	1,250		$	—	$	—

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consisted of the following:
	(in thousands)	June 30,		December 31,
		2014		2013
	Furniture and equipment	$	32	$	32
	Computers and IT equipment		92		86
	Purchased software		674		674
	Lab and research equipment		2,695		2,695
	Leasehold improvements		336		336
	Other fixed assets		35		35
			3,864		3,858
	Less: Accumulated depreciation and amortization		1,762		1,529
	Property and equipment, net	$	2,102	$	2,329
	For each of the three months ended June 30, 2014 and 2013, total depreciation and amortization expense was $0.1 million, and $0.2 million for each of the six months ended June 30, 2014 and 2013, which is included in selling, general and administrative expenses and research and development in the accompanying Statements of Operations as follows:
		For the three months ended				For the six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	(in thousands)
	Selling, general and administrative	$	100	$	67	$	192	$	137
	Research and development		17		48		41		92
	Total depreciation and amortization expense	$	117	$	115	$	233	$	229

Notes_Receivable_from_Related_

Notes Receivable from Related Parties	6 Months Ended
	Jun. 30, 2014
Notes Receivable from Related Parties	'
	4. Notes Receivable from Related Parties
	On January 21, 2010, the Company issued promissory notes (“Notes”) to certain officers and employees totaling $87 thousand in principal related to the payment of personal taxes associated with the restricted shares of common stock issued to these respective employees as discussed in Note 10—Stock-Based Compensation. The principal balance of the Notes are due together with accrued and unpaid interest on the earliest of: (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Note, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party. The Notes bear simple interest at 2.45% per annum. In June 2014, the Company’s Board of Directors approved the forgiveness of the principal amount and any accrued interest for each Note and to gross up each affected employee’s compensation, in full, for any withholding tax obligations incurred in connection with such Note forgiveness. The total charge of $157 thousand for the write-off of the notes, interest receivable, and related tax forgiveness was recorded in June 2014 and has been included in selling, general and administrative expenses in the accompanying Statement of Operations. The composition of notes receivable balance as of June 30, 2014 and December 31, 2013 was as follows:
	(in thousands)	June 30,		December 31,
		2014		2013
	Principal balance	$	—	$	87
	Accrued and unpaid interest		—		8
	Total notes receivable	$	—	$	95

Intangible_Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2014
Intangible Assets	'
	5. Intangible Assets
	Intangible assets consisted of the following:
	(in thousands)	June 30,			December 31,
		2014			2013
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910
	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,432	)		(2,167	)
	Total intangible assets, net	$	6,628		$	6,893
	Amortization expense was $133 thousand for each of the three months ended June 30, 2014 and 2013 and $0.3 million for each of the six months ended June 30, 2014 and 2013. Amortization expense is included within selling, general and administrative expense in the accompanying Statements of Operations. As of June 30, 2014, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities	'
	6. Accrued Liabilities
	Accrued liabilities consisted of the following:
	(in thousands)	June 30, 2014		December 31,
				2013
	Accrued vacation	$	342	$	321
	Deferred rent		240		238
	Other accrued employee-related liabilities		1,297		771
	Accrued professional fees		543		191
	Accrued supplier liability		1,034		747
	Accrued subcontractor costs		560		526
	Other accrued liabilities		554		159
		$	4,570	$	2,953

Lines_of_Credit_Obligation

Lines of Credit Obligation	6 Months Ended
	Jun. 30, 2014
Lines of Credit Obligation	'
	7. Lines of Credit Obligation
	The Company entered into two Revolving Line of Credit agreements with Wells Fargo Bank, National Association (“Wells Fargo”). The first LOC was entered into in May 2012 (“2012 LOC”) and the second in June 2013 (“2013 LOC”). The maximum capacity for the 2012 LOC and 2013 LOC is $1.5 million and $2.4 million, for a total capacity of $3.9 million. Both LOCs are collateralized by money market accounts held at Wells Fargo. The documents governing the credit facilities contain covenants. The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company’s 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer. On April 2, 2014, the Company obtained from Wells Fargo a waiver for the covenants and confirmation that the Company may repurchase common stock up to a maximum of $0.5 million. On June 24, 2014, the Company entered into an amendment to the credit facilities which allows us to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of our stock in connection with the Company’s initial public offering.
	As of June 30, 2014, the amount drawn down on the lines of credit was $1.4 million and $2.4 million for the 2012 LOC and the 2013 LOC, respectively, for a total outstanding amount of $3.8 million. Both lines of credit are due and payable in April 2015. As of June 30, 2014, the 2012 LOC was bearing a fixed interest rate of 2.00% above LIBOR, or 2.25%. As of June 30, 2014, the 2013 LOC was bearing fixed interest rates ranging from 2.25% to 2.375% as of that date. The Company recognized $41 thousand and $14 thousand of interest expense related to the LOCs for the six months ended June 30, 2014 and 2013 and $22 thousand and $7 thousand for the three months ended June 30, 2014 and 2013, respectively.

Common_Stock_and_Preferred_Sto

Common Stock and Preferred Stock	6 Months Ended
	Jun. 30, 2014
Common Stock and Preferred Stock	'
	8. Common Stock and Preferred Stock
	Prior to the completion of its initial public offering in July 2014, the Company was authorized to issue common stock and Series A-1 and Series A-2 redeemable convertible preferred stock. Immediately prior to the completion of the Company’s initial public offering, all of the outstanding shares of convertible preferred stock automatically converted into 8,634,857 shares of common stock. The Company issued 1,217,784 shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock immediately prior to the completion of the initial public offering. Members of our management team also forfeited an aggregate of 100,000 shares of common stock in connection with the completion of the initial public offering.
	Common Stock
	Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of other classes of stock outstanding.
	Preferred Stock
	Pursuant to the amended and restated certificate of incorporation filed by the Company immediately prior to the completion of its initial public offering, the Company’s board of directors is authorized to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in the Company’s control or other corporate action.
	Series A-1 and A-2 Redeemable Convertible Preferred Stock
	The Series A-1 and A-2 preferred stock had a contingent redemption feature allowing redemption by the holders at any time after December 31, 2014 upon the affirmative vote of sixty-six and two thirds (66  2⁄3%) of the holders. As the event that would trigger the redemption of the redeemable convertible preferred stock was not solely within the Company’s control, the redeemable convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Company’s balance sheet. The shares are to be redeemed by paying cash in an amount per share equal to the greater of (i) the Series A original issue price and any Series A dividends accrued but unpaid and (ii) the then-current fair market value of such shares.
	The Company immediately recognized the changes in the redemption value as they occurred and the carrying value of the security was adjusted to equal what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that exist as of that date. There was no limit to the maximum amount the Company could be required to pay. The value adjustments made to the redemption values at June 30, 2014 and December 31, 2013 were increases of $0.8 million and $71.0 million, respectively.
	Series A-1 stock was subject to a cumulative dividend of four percent (4%) compounded quarterly, whether or not declared. Each share of Series A-1 stock was convertible into 0.91966 shares of common stock, subject to adjustments for certain dilutive events. Series A-2 stock was subject to a cumulative dividend of eight percent (8%) compounded quarterly, whether or not declared. Each share of Series A-2 stock was convertible into 1.1406 shares of common stock, subject to adjustments for certain dilutive events.
	As of June 30, 2014 and December 31, 2013, there had been no conversions of redeemable convertible preferred stock to common stock by either Series A-1 or Series A-2 stockholders, and there were no dilutive issuances of common stock.
	As of June 30, 2014, there were cumulative unpaid dividends of $7.2 million for the Series A-1 and Series A-2 redeemable convertible preferred stock.
	As of June 30, 2014 and December 31, 2013, no dividends had been declared or paid. Cumulative dividends as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
		Cumulative as of June 30, 2014				Cumulative as of December 31, 2013
	(in thousands except dividends per share)	Dividends		Dividends		Dividends		Dividends
				per Share				per Share
	Series A-2	$	4,369	$	1.23	$	3,815	$	1.07
	Series A-1		2,798		0.56		2,470		0.5
		$	7,167			$	6,285
	In July 2014, the Company completed its initial public offering. In connection with the initial public offering, the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends on the preferred stock through July 28, 2014.

Commitment_to_Repurchase_Stock

Commitment to Repurchase Stock	6 Months Ended
	Jun. 30, 2014
Commitment to Repurchase Stock	'
	9. Commitment to Repurchase Stock
	On December 1, 2009, the Company entered into a common stock subscription agreement with three investors (“Investors”) pursuant to which the Company agreed to repurchase a maximum of 423,185 shares of common stock at a price per share of $0.31. Pursuant to the amended and restated subscription agreement, dated May 2, 2014, the Company repurchased all 423,185 shares of common stock at $0.31 price per share immediately prior to the completion of the Company’s initial public offering in July 2014. The total cost of the repurchase was $131 thousand.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation	'
	10. Stock-Based Compensation
	Stock Options
	Total stock based compensation expense associated with stock options granted was $76 thousand and $14 thousand for the three months ended June 30, 2014 and 2013, respectively, and $84 thousand and $27 thousand for the six months ended June 30, 2014 and 2013, respectively.
	The exercise price of all options granted during the three and six months ended June 30, 2014 and 2013 was equal to the estimated fair value of the underlying common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period.
	As of June 30, 2014, total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $1.4 million, which is expected to be recognized over a weighted average period of approximately 3.9 years.
	During the six months ended June 30, 2014 and 2013, stock options to purchase approximately 30 thousand and 62 thousand shares of the Company’s common stock were exercised, respectively. The cash received by the Company from stock option exercises during the six months ended June 30, 2014 and 2013 was approximately $9 thousand and $24 thousand, respectively.
	In July 2014, our board of directors adopted a 2014 Equity Incentive Plan, or the 2014 Plan, and our stockholders approved it. Our 2014 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to our employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees, directors and consultants and our parent and subsidiary corporations’ employees and consultants. A total of 1,356,219 shares of our common stock have been reserved for issuance pursuant to the 2014 Plan. In July 2014, our board of directors adopted a 2014 Employee Stock Purchase Plan, or the ESPP, and our stockholders approved it. A total of 355,618 shares of our common stock have been reserved for sale under the ESPP. In addition, our ESPP provides for annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015.
	Stock Option Assumption
	The Company granted stock options to purchase approximately 259 thousand and 36 thousand shares of the Company’s common stock during the six months ended June 30, 2014 and 2013, respectively. These stock options generally vest monthly over a four-year period. The exercise price of all stock options granted during the six months ended June 30, 2014 and 2013 was equal to the estimated fair value of the Company’s common stock on the date of grant. The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants:
	The following assumptions were used to estimate the fair value of stock options:
		Three Months Ended June 30,			Six Months Ended June 30,
		2014	2013		2014	2013
	Risk-free interest rate	1.9% –2.0%		—	1.9% –2.0%		1.2	%
	Expected volatility	48.7% –53.5%		—	48.7% – 53.5%		54.4	%
	Expected forfeiture rate	3.23%		—	3.23%		1.9	%
	Expected dividend yield	0%		—	0%		0	%
	Expected life of options in years	5.5 – 6.1		—	5.5 – 6.1		6.1
	The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model requires multiple subjective inputs, including a measure of expected future volatility. Until July 2014, the Company’s stock did not have a readily available market. Consequently, the expected future volatility was based on the historical volatility for comparable publically traded companies over the most recent period commensurate with the estimated expected term of the Company’s stock options.
	The risk-free interest rate assumption is based upon observed interest rates during the period appropriate for the expected term of the options. The expected term of options granted represents the period of time the options are expected to be outstanding. With the exception of the dividend paid in connection with the conversion of all preferred stock upon the completion of the Company’s initial public offering, the Company has never declared or paid dividends and has no plans to do so in the foreseeable future. Accordingly, the dividend yield assumption is based on the expectation that the Company will not pay dividends in the future. Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the six months ended June 30, 2014 and 2013, share-based compensation expense related to stock options was $84 thousand and $27 thousand, respectively.
	Restricted Stock Awards
	In January 2010, the Company granted 1,034,850 shares of restricted stock to certain officers and employees with an estimated value of $0.31 per share, or $0.3 million. No restricted stock was granted during 2012 or 2013. Compensation expense is recognized for grants of restricted stock awards using the estimated value of the Company’s stock on the date of grant. Stock compensation is recognized on a straight line basis over the vesting period, which is generally four years. As of December 31, 2013, all 1,034,850 shares were fully vested. The stock-based compensation expense related to these restricted stock awards amounted to $40 thousand for the six months ended June 30, 2013. As these restricted stock awards were fully vested by December 31, 2013, there was no related compensation expense for the six months ended June 30, 2014.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
	11. Net Loss Per Share
	The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. Additionally, potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options, are excluded from the diluted loss per share calculation because of their anti-dilutive effect.
	For the three and six months ended June 30, 2014, the Company realized a net loss of $2.2 million and $3.7 million, respectively. Potentially dilutive securities totaled approximately 1.0 million for the both the three and six months ended June 30, 2014.
	For the three and six months ended June 30, 2013, the Company realized a net loss of $1.2 million and $1.9 million, respectively. Potentially dilutive securities totaled approximately 0.7 million, respectively, for both the three and six months ended June 30, 2013.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	12. Subsequent Events
	In July 2014, the Company completed its initial public offering pursuant to which it sold 9,429,084 shares of its common stock (inclusive of 1,095,751 shares of common stock from the exercise of the underwriters’ option to purchase additional shares) at a public offering price of $6.00 per share, resulting in net proceeds of approximately $52.6 million, after underwriting discounts and commissions but before offering expenses of approximately $2.3 million. In connection with the initial public offering, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
	The Company has evaluated all subsequent events that have occurred after the date of the accompanying financial statements and determined that with the exception of the events disclosed herein, there are no additional events or transactions occurring during this subsequent event reporting period which require recognition or disclosure in the Company’s financial statements.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Business Activities and Organization	'
	Business Activities and Organization
	Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. Pfenex is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc. a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with trial completion expected in the fourth quarter of 2014, and expects to commence a Phase 3 trial in mid-2015 with results expected in 2017. The Company intends to commercialize PF582 with its own internal sales and marketing capabilities in North America and Europe. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. The Company plans to initiate a Phase 1 trial in the second half of 2014. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates.
	The Company’s revenue is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
Reverse Stock Split	'
	Reverse Stock Split
	On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.
Initial Public Offering	'
	Initial Public Offering
	In July 2014, the Company completed its initial public offering in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.3 million. In connection with the initial public offering, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed financial statements included the accounts of the Company and its wholly owned subsidiary.
	These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013 included in the Company’s Prospectus filed with the SEC on July 24, 2014 pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2013 has been derived from the audited financial statement at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
Use of Estimates	'
	Use of Estimates
	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
Restricted Cash	'
	Restricted Cash
	In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”). Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013. The two lines of credit are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the lines of credit are paid in full and have expired. The lines of credit are due and payable in full in April 2015.
Concentrations	'
	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of June 30, 2014 and December 31, 2013. For the Company’s cash position of $8.0 million as of June 30, 2014, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.
	Additional credit risk is related to the Company’s concentration of receivables. As of June 30, 2014, receivables were concentrated among two customers representing 87% of total gross receivables and three customers as of December 31, 2013, representing 83%. For the six month period ended June 30, 2014, revenue was concentrated among two customers representing 78% of total revenues and three customers representing 72% for the six months ended June 30, 2013. Revenue was concentrated among two customers for each of the three months ended June 30, 2014 and 2013, representing 80% and 57% of total revenue, respectively. There were no supplier concentrations.
	A portion of revenue is earned from sales outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the three and six months ended June 30, 2013 and 2014 is as follows (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	US Revenue	$	2,931	$	1,944	$	5,158	$	3,237
	Non-US Revenue	$	335	$	365	$	666	$	2,457
	During the three and six months ended June 30, 2014, and the three months ended June 30, 2013, no single foreign country accounted for more than 10% of the Company’s revenue. During the six months ended June 30, 2013, revenue earned from non-recurring sales in The Netherlands accounted for approximately 15% of the Company’s revenue.
Inventories	'
	Inventories
	Inventories consist of work in progress and finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the six months ended June 30, 2014 or the year ended December 31, 2013.
Revenue	'
	Revenue
	The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for milestones and product royalties.
	The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.
	Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.
	Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.
	The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under our government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
	The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the three and six months ended June 30, 2014, and 2013, no revenue in connection with the achievement of milestones has been recognized.
	The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 90 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. Reagent product revenue amounted to $0.3 million and $0.2 million for the three months ended June 30, 2014 and 2013, respectively, and $0.8 million and $2.3 million for the six months ended June 30, 2014 and 2013, respectively. As of June 30, 2014, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has deemed it prudent to reserve $14 thousand and $18 thousand for warranty and return rights at June 30, 2014 and December 31, 2013, respectively. The reserve is component of accounts and unbilled receivables, net in the accompanying Balance Sheets.
	Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting recording the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be the first quarter of fiscal year 2018 using one of two retrospective application methods. The Company is currently evaluating the impact of the adoption of this accounting standard update on its financial statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Sales Revenue	'
	A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the three and six months ended June 30, 2013 and 2014 is as follows (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	US Revenue	$	2,931	$	1,944	$	5,158	$	3,237
	Non-US Revenue	$	335	$	365	$	666	$	2,457

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Cash and Investments Measured at Fair Value on Recurring Basis	'
	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013, were determined using the inputs described above and are as follows:
		Total			Fair Value Measurements at Reporting Date Using
	(in thousands)				Quoted Prices			Significant		Significant
					in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical Assets			Inputs		(Level 3)
					(Level 1)			(Level 2)
	June 30, 2014
	Classified as current assets:
	Cash and money market funds	$	7,971		$	7,971		$	—	$	—
	Certificates of deposit		—			—			—		—
	Total		7,971			7,971			—		—
	Less cash, cash equivalents and restricted cash		(7,971	)		(7,971	)		—		—
	Total investments	$	—		$	—		$		$	—
	December 31, 2013
	Classified as current assets:
	Cash and money market funds	$	7,983		$	7,983		$	—	$	—
	Certificates of deposit		1,250			1,250			—		—
	Total		9,233			9,233			—		—
	Less cash, cash equivalents and restricted cash		(7,983	)		(7,983	)		—		—
	Total investments	$	1,250		$	1,250		$	—	$	—

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Property and Equipment	'
	Property and equipment consisted of the following:
	(in thousands)	June 30,		December 31,
		2014		2013
	Furniture and equipment	$	32	$	32
	Computers and IT equipment		92		86
	Purchased software		674		674
	Lab and research equipment		2,695		2,695
	Leasehold improvements		336		336
	Other fixed assets		35		35
			3,864		3,858
	Less: Accumulated depreciation and amortization		1,762		1,529
	Property and equipment, net	$	2,102	$	2,329
	For each of the three months ended June 30, 2014 and 2013, total depreciation and amortization expense was $0.1 million, and $0.2 million for each of the six months ended June 30, 2014 and 2013, which is included in selling, general and administrative expenses and research and development in the accompanying Statements of Operations as follows:
		For the three months ended				For the six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	(in thousands)
	Selling, general and administrative	$	100	$	67	$	192	$	137
	Research and development		17		48		41		92
	Total depreciation and amortization expense	$	117	$	115	$	233	$	229

Notes_Receivable_from_Related_1

Notes Receivable from Related Parties (Tables)	6 Months Ended
	Jun. 30, 2014
Composition of Notes Receivable Balance	'
	The composition of notes receivable balance as of June 30, 2014 and December 31, 2013 was as follows:
	(in thousands)	June 30,		December 31,
		2014		2013
	Principal balance	$	—	$	87
	Accrued and unpaid interest		—		8
	Total notes receivable	$	—	$	95

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Intangible Assets	'
	Intangible assets consisted of the following:
	(in thousands)	June 30,			December 31,
		2014			2013
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910
	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,432	)		(2,167	)
	Total intangible assets, net	$	6,628		$	6,893

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Components of Accrued Liabilities	'
	Accrued liabilities consisted of the following:
	(in thousands)	June 30, 2014		December 31,
				2013
	Accrued vacation	$	342	$	321
	Deferred rent		240		238
	Other accrued employee-related liabilities		1,297		771
	Accrued professional fees		543		191
	Accrued supplier liability		1,034		747
	Accrued subcontractor costs		560		526
	Other accrued liabilities		554		159
		$	4,570	$	2,953

Common_Stock_and_Preferred_Sto1

Common Stock and Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Cumulative Dividends	'
	Cumulative dividends as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
		Cumulative as of June 30, 2014				Cumulative as of December 31, 2013
	(in thousands except dividends per share)	Dividends		Dividends		Dividends		Dividends
				per Share				per Share
	Series A-2	$	4,369	$	1.23	$	3,815	$	1.07
	Series A-1		2,798		0.56		2,470		0.5
		$	7,167			$	6,285

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Assumptions used to Estimate Fair Value of Stock Options	'
	The following assumptions were used to estimate the fair value of stock options:
		Three Months Ended June 30,			Six Months Ended June 30,
		2014	2013		2014	2013
	Risk-free interest rate	1.9% –2.0%		—	1.9% –2.0%		1.2	%
	Expected volatility	48.7% –53.5%		—	48.7% – 53.5%		54.4	%
	Expected forfeiture rate	3.23%		—	3.23%		1.9	%
	Expected dividend yield	0%		—	0%		0	%
	Expected life of options in years	5.5 – 6.1		—	5.5 – 6.1		6.1

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional information (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 27, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Credit Availability Concentration Risk [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

NETHERLANDS

IPO [Member]

IPO [Member]

Underwriters' Option [Member]

Reagent [Member]

Reagent [Member]

Reagent [Member]

Reagent [Member]

Customer

Customer

Customer

Customer

Customer

Customer

Sales Revenue, Net [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Geographic Concentration Risk [Member]

Redeemable Convertible Preferred Stock [Member]

Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

0.3556

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares issued

'

1,571,473

'

1,571,473

'

1,541,781

'

'

'

'

'

'

'

'

8,333,333

'

'

'

'

'

'

Common stock price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,429,084

'

1,095,751

'

'

'

'

Proceeds from issuance initial public offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$52,600,000

'

'

'

'

'

'

Offering expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

Convertible preferred stock shares converted to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,634,857

'

'

'

'

'

Common stock issued in connection with payment of dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,217,784

1,217,784

'

'

'

'

'

Common stock repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

423,185

'

'

'

'

'

'

Common stock purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.31

'

'

'

'

'

'

Number of shares forfeited

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Cash

'

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of customers accounted for receivables

'

'

'

'

'

'

'

2

3

'

'

'

'

'

'

'

'

'

'

'

'

Number of customers accounted for revenue

'

'

'

'

'

'

'

'

'

2

2

2

3

'

'

'

'

'

'

'

'

Concentration of risk percentage

'

'

'

'

'

'

'

87.00%

83.00%

80.00%

57.00%

78.00%

72.00%

15.00%

'

'

'

'

'

'

'

Inventory write downs

'

'

'

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue recognized

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Product revenue

'

3,266,000

2,309,000

5,824,000

5,694,000

'

'

'

'

'

'

'

'

'

'

'

'

300,000

200,000

800,000

2,300,000

Warrants reserve accrual

'

$14,000

'

$14,000

'

$18,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Sales_Revenue_Detai

Summary of Sales Revenue (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Concentration Risk [Line Items]	'	'	'	'
Revenue	$3,266	$2,309	$5,824	$5,694
Geographic Concentration Risk [Member] | US [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Revenue	2,931	1,944	5,158	3,237
Geographic Concentration Risk [Member] | Non - US [Member]	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Revenue	$335	$365	$666	$2,457

Cash_and_Investments_Measured_

Cash and Investments Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	$7,971	$9,233
Less cash, cash equivalents and restricted cash	-7,971	-7,983
Total investments	'	1,250
Cash And Money Market Funds [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	7,971	7,983
Certificates of Deposit [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	'	1,250
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	7,971	9,233
Less cash, cash equivalents and restricted cash	-7,971	-7,983
Total investments	'	1,250
Fair Value, Inputs, Level 1 [Member] | Cash And Money Market Funds [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	7,971	7,983
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]	'	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'	'
Assets fair value disclosure	'	$1,250

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	$3,864	$3,858
Less: Accumulated depreciation and amortization	1,762	1,529
Property and equipment, net	2,102	2,329
Furniture And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	32	32
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	92	86
Computer Software, Intangible Asset [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	674	674
Research And Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	2,695	2,695
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	336	336
Other Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	$35	$35

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Total depreciation and amortization expense	$117	$115	$233	$229

Depreciation_and_Amortization_

Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Total depreciation and amortization expense	$117	$115	$233	$229
Selling, General and Administrative Expenses [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Total depreciation and amortization expense	100	67	192	137
Research and Development Expense [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Total depreciation and amortization expense	$17	$48	$41	$92

Notes_Receivable_from_Related_2

Notes Receivable from Related Parties - Additional Information (Detail) (Officers and Employees [Member], USD $)	0 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jan. 21, 2010	Jun. 30, 2014	Dec. 31, 2013	Jan. 21, 2010
Officers and Employees [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Principal amount of note issued	'	'	$87	$87
Debt instrument due date, Description	'The principal balance of the Notes are due together with accrued and unpaid interest on the earliest of (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Note, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party.	'	'	'
Interest rate	'	'	'	2.45%
Charge for write-offs	'	$157	'	'

Composition_of_Notes_Receivabl

Composition of Notes Receivable Balance (Detail) (Officers and Employees [Member], USD $)	Dec. 31, 2013	Jan. 21, 2010
In Thousands, unless otherwise specified
Officers and Employees [Member]	'	'
Related Party Transaction [Line Items]	'	'
Principal balance	$87	$87
Accrued and unpaid interest	8	'
Total notes receivable	$95	'

Intangible_Assets_Summary_of_I

Intangible Assets - Summary of Intangible Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross intangible assets	$9,060	$9,060
Less: Accumulated amortization	-2,432	-2,167
Total intangible assets, net	6,628	6,893
Trade Names [Member]	'	'
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross intangible assets	910	910
Customer Relationships [Member]	'	'
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross intangible assets	3,750	3,750
Developed Technology [Member]	'	'
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]	'	'
Gross intangible assets	$4,400	$4,400

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of intangible assets	'	'	$265,000	$265,000
Estimated amortization expense, 2015	500,000	'	500,000	'
Estimated amortization expense, 2016	500,000	'	500,000	'
Estimated amortization expense, 2017	500,000	'	500,000	'
Estimated amortization expense, 2018	500,000	'	500,000	'
Estimated amortization expense, 2019	500,000	'	500,000	'
Selling, General and Administrative Expenses [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of intangible assets	$133,000	$133,000	$300	$300

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued vacation	$342	$321
Deferred rent	240	238
Other accrued employee-related liabilities	1,297	771
Accrued professional fees	543	191
Accrued supplier liability	1,034	747
Accrued subcontractor costs	560	526
Other accrued liabilities	554	159
Accrued liabilities	$4,570	$2,953

Lines_of_Credit_Obligation_Add

Lines of Credit Obligation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended			6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 24, 2014	Apr. 02, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
					Maximum [Member]	Maximum [Member]	2012 LOC [Member]	2012 LOC [Member]	2013 LOC [Member]	2013 LOC [Member]	2013 LOC [Member]
								London Interbank Offered Rate (LIBOR) [Member]		Maximum [Member]	Minimum [Member]
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Line of credit facility, Maximum borrowing capacity	$3,900,000	'	$3,900,000	'	'	'	$1,500,000	'	$2,400,000	'	'
Line of credit facility, covenant compliance	'	'	'The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company's 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer.	'	'	'	'	'	'	'	'
Line of credit covenant, common stock repurchase allowed	'	'	'	'	'	500,000	'	'	'	'	'
Line of credit covenant, operating lease expenses allowed to be incurred	'	'	'	'	600,000	'	'	'	'	'	'
Line of credit covenant description	'	'	'On June 24, 2014, the Company entered into an amendment to the credit facilities which allows us to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of our stock in connection with the Company's initial public offering.	'	'	'	'	'	'	'	'
Line of credit total outstanding amount	3,813,000	'	3,813,000	'	'	'	1,400,000	'	2,400,000	'	'
Line of credit facility, basis spread	'	'	'	'	'	'	'	2.00%	'	'	'
Line of credit bearing a fixed interest rate	'	'	'	'	'	'	2.25%	'	'	2.38%	2.25%
Interest expense	$22,000	$7,000	$41,000	$14,000	'	'	'	'	'	'	'

Common_Stock_and_Preferred_Sto2

Common Stock and Preferred Stock - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended	1 Months Ended	6 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended	1 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jul. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jul. 31, 2014
	Vote		Subsequent Event [Member]	Series A-1 [Member]	Series A-1 [Member]	Series A-2 [Member]	Series A-2 [Member]	Redeemable Convertible Preferred Stock [Member]
			IPO [Member]					Subsequent Event [Member]
								IPO [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Common stock issued in connection with conversion of preferred stock	'	'	'	'	'	'	'	8,634,857
Common stock issued in connection with payment of dividends	'	'	1,217,784	'	'	'	'	1,217,784
Number of shares forfeited	'	'	100,000	'	'	'	'	'
Votes entitled for every common stock	1	'	'	'	'	'	'	'
Preferred stock authorized	10,000,000	'	'	'	'	'	'	'
Preferred stock, redemption terms	'The Series A-1 and A-2 preferred stock had a contingent redemption feature allowing redemption by the holders at any time after December 31, 2014 upon the affirmative vote of sixty-six and two thirds (66 2b 3%) of the holders. As the event that would trigger the redemption of the redeemable convertible preferred stock was not solely within the Companybs control, the redeemable convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Companybs consolidated balance sheet. The shares are to be redeemed by paying cash in an amount per share equal to the greater of (i) the Series A original issue price and any Series A dividends accrued but unpaid and (ii) the then-current fair market value of such shares.	'	'	'	'	'	'	'
Affirmative vote required for redemption	66.67%	'	'	'	'	'	'	'
Adjustments made to the redemption values	$800,000	$71,000,000	'	'	'	'	'	'
Preferred stock dividend rate, cumulative percentage	'	'	'	4.00%	'	8.00%	'	'
Preferred stock conversion ratio for each share	'	'	'	0.91966	'	1.1406	'	'
Convertible preferred stock shares converted to common stock	'	'	'	0	0	0	0	'
Issuance of dilutive common stock	0	0	'	'	'	'	'	'
Cumulative unpaid dividends	7,167,000	6,285,000	'	2,798,000	2,470,000	4,369,000	3,815,000	'
Dividend declared or paid	$0	$0	'	'	'	'	'	'

Summary_of_Cumulative_Dividend

Summary of Cumulative Dividends (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Dividends Payable [Line Items]	'	'
Dividends	$7,167	$6,285
Series A-2 [Member]	'	'
Dividends Payable [Line Items]	'	'
Dividends	4,369	3,815
Dividends per Share	$1.23	$1.07
Series A-1 [Member]	'	'
Dividends Payable [Line Items]	'	'
Dividends	$2,798	$2,470
Dividends per Share	$0.56	$0.50

Commitment_to_Repurchase_Stock1

Commitment to Repurchase Stock - Additional Information (Detail) (Common Stock [Member], USD $)	Dec. 01, 2009	Jul. 31, 2014
In Thousands, except Share data, unless otherwise specified	Maximum [Member]	Subsequent Event [Member]
Equity, Class of Treasury Stock [Line Items]	'	'
Number of shares authorized to be repurchased	423,185	'
Share price	$0.31	'
Common stock purchase price	'	$0.31
Shares repurchased	'	423,185
Total cost of repurchase	'	$131

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended		6 Months Ended			6 Months Ended
	Jan. 31, 2010	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	Jul. 31, 2014	Jul. 31, 2014	Jun. 30, 2014
								Employee Stock Option [Member]	2014 Equity Incentive Plan [Member]	2014 Employee Stock Purchase Plan [Member]	Restricted Stock [Member]
									Subsequent Event [Member]	Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Stock based compensation expense associated with stock options	'	$76,000	$14,000	$84,000	$27,000	'	'	'	'	'	'
Unrecognized estimated compensation cost related to non-vested stock options	'	1,400,000	'	1,400,000	'	'	'	'	'	'	'
Unrecognized estimated compensation cost related to non-vested stock options, weighted average period for recognition	'	'	'	'3 years 10 months 24 days	'	'	'	'	'	'	'
Stock options exercised, shares	'	'	'	30,000	62,000	'	'	'	'	'	'
Cash received from stock option exercises	'	'	'	9,000	24,000	'	'	'	'	'	'
Shares reserved for issuance	'	'	'	'	'	'	'	'	1,356,219	355,618	'
Stock options to purchase common stock, granted	'	'	'	259,000	36,000	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'	'	'	'	'4 years	'	'	'4 years
Restricted stock, Granted shares	1,034,850	'	'	'	'	0	0	'	'	'	'
Restricted stock, Granted estimated value	$0.31	'	'	'	'	'	'	'	'	'	'
Restricted stock, granted amount	300,000	'	'	'	'	'	'	'	'	'	'
Restricted stock, vested shares	'	'	'	'	'	1,034,850	'	'	'	'	'
Restricted stock, stock based compensation expense	'	'	'	$0	$40,000	'	'	'	'	'	'

Assumptions_used_to_Estimate_F

Assumptions used to Estimate Fair Value of Stock Options (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate, minimum	1.90%	1.90%	'
Risk-free interest rate, maximum	2.00%	2.00%	'
Risk-free interest rate	'	'	1.20%
Expected volatility, minimum	48.70%	48.70%	'
Expected volatility, maximum	53.50%	53.50%	'
Expected volatility	'	'	54.40%
Expected forfeiture rate	3.23%	3.23%	1.90%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of options in years	'	'	'6 years 1 month 6 days
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected life of options in years	'5 years 6 months	'5 years 6 months	'
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected life of options in years	'6 years 1 month 6 days	'6 years 1 month 6 days	'

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Schedule Of Earnings Per Share Basic And Diluted [Line Items]	'	'	'	'
Net Income (Loss)	($2,183,000)	($1,177,000)	($3,725,000)	($1,903,000)
Potentially dilutive securities	$1,000,000	$700,000	$1,000,000	$700,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (IPO [Member], USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 31, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Issuance of stock (in shares)	9,429,084
Common stock price, per share	$6
Proceeds from issuance initial public offering	$52.60
Offering expense	$2.30
Common stock issued in connection with payment of dividends	1,217,784
Common stock repurchased	423,185
Common stock purchase price	$0.31
Number of shares forfeited	100,000
Subsequent Event [Member] | Redeemable Convertible Preferred Stock [Member]	'
Subsequent Event [Line Items]	'
Convertible preferred stock shares converted to common stock	8,634,857
Common stock issued in connection with payment of dividends	1,217,784
Underwriters' Option [Member]	'
Subsequent Event [Line Items]	'
Issuance of stock (in shares)	1,095,751